Shefali Agarwal, See Remarks at Epizyme, Inc. (EPZM), sold 2,639 shares at $1.37 ($4K) on 2022-02-02, disclosed to the SEC on 2022-02-04.
Scheduled sale ($4k) by See Remarks under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| EPZM | SELL | 2022-02-09 | $2K | — | Filing → |
| EPZM | SELL | 2022-01-28 | $6K | — | Filing → |
| EPZM | SELL | 2021-12-07 | $5K | — | Filing → |